AroCell AB (publ) (AROC.ST)
SEK 0.38
(-4.98%)
SEK 0.38
(-4.98%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.26 SEK | 3.7% |
| 2022 | -0.27 SEK | 48.08% |
| 2021 | -0.52 SEK | -100.0% |
| 2020 | -0.26 SEK | 35.0% |
| 2019 | -0.40 SEK | 21.57% |
| 2018 | -0.51 SEK | 12.07% |
| 2017 | -0.58 SEK | -87.1% |
| 2016 | -0.31 SEK | -24.0% |
| 2015 | -0.25 SEK | 3.85% |
| 2014 | -0.26 SEK | -36.84% |
| 2013 | -0.19 SEK | 13.64% |
| 2012 | -0.22 SEK | 48.84% |
| 2011 | -0.43 SEK | 0.0% |
| 2010 | -0.43 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.05 SEK | 38.71% |
| 2024 Q3 | -0.04 SEK | 24.69% |
| 2024 Q2 | -0.06 SEK | -24.34% |
| 2023 FY | - SEK | 3.7% |
| 2023 Q3 | -0.06 SEK | 16.07% |
| 2023 Q2 | -0.07 SEK | -13.32% |
| 2023 Q4 | -0.07 SEK | -31.91% |
| 2023 Q1 | -0.06 SEK | 17.29% |
| 2022 Q1 | -0.09 SEK | 61.92% |
| 2022 Q4 | -0.07 SEK | -43.4% |
| 2022 Q3 | -0.05 SEK | 27.54% |
| 2022 Q2 | -0.07 SEK | 24.51% |
| 2022 FY | - SEK | 48.08% |
| 2021 Q1 | -0.08 SEK | -6.36% |
| 2021 Q3 | -0.20 SEK | -122.22% |
| 2021 Q4 | -0.24 SEK | -20.0% |
| 2021 FY | - SEK | -100.0% |
| 2021 Q2 | -0.09 SEK | -12.08% |
| 2020 Q1 | -0.08 SEK | 45.8% |
| 2020 Q4 | -0.08 SEK | 3.82% |
| 2020 FY | - SEK | 35.0% |
| 2020 Q3 | -0.08 SEK | 4.03% |
| 2020 Q2 | -0.08 SEK | -0.62% |
| 2019 Q4 | -0.15 SEK | -36.36% |
| 2019 Q3 | -0.11 SEK | 8.33% |
| 2019 FY | - SEK | 21.57% |
| 2019 Q1 | -0.12 SEK | 36.84% |
| 2019 Q2 | -0.12 SEK | 0.0% |
| 2018 Q1 | -0.14 SEK | 30.0% |
| 2018 Q2 | -0.17 SEK | -21.43% |
| 2018 FY | - SEK | 12.07% |
| 2018 Q4 | -0.19 SEK | -46.15% |
| 2018 Q3 | -0.13 SEK | 23.53% |
| 2017 Q4 | -0.20 SEK | -53.85% |
| 2017 FY | - SEK | -87.1% |
| 2017 Q3 | -0.13 SEK | -8.33% |
| 2017 Q2 | -0.12 SEK | 20.0% |
| 2017 Q1 | -0.15 SEK | -65.56% |
| 2016 FY | - SEK | -24.0% |
| 2016 Q1 | -0.10 SEK | -46.63% |
| 2016 Q2 | -0.07 SEK | 31.6% |
| 2016 Q3 | -0.09 SEK | -31.58% |
| 2016 Q4 | -0.09 SEK | -0.67% |
| 2015 FY | - SEK | 3.85% |
| 2015 Q2 | -0.07 SEK | 29.9% |
| 2015 Q1 | -0.10 SEK | 28.57% |
| 2015 Q4 | -0.07 SEK | 11.66% |
| 2015 Q3 | -0.08 SEK | -10.13% |
| 2014 Q1 | -0.06 SEK | 30.96% |
| 2014 Q4 | -0.14 SEK | -150.45% |
| 2014 FY | - SEK | -36.84% |
| 2014 Q3 | -0.06 SEK | 18.39% |
| 2014 Q2 | -0.07 SEK | -19.55% |
| 2013 FY | - SEK | 13.64% |
| 2013 Q1 | -0.06 SEK | 11.87% |
| 2013 Q4 | -0.08 SEK | -245.83% |
| 2013 Q3 | -0.02 SEK | 48.94% |
| 2013 Q2 | -0.05 SEK | 20.88% |
| 2012 Q1 | -0.09 SEK | 38.43% |
| 2012 Q2 | -0.07 SEK | 16.59% |
| 2012 Q4 | -0.07 SEK | -80.21% |
| 2012 Q3 | -0.04 SEK | 47.98% |
| 2012 FY | - SEK | 48.84% |
| 2011 Q2 | -0.15 SEK | -7.14% |
| 2011 Q3 | -0.06 SEK | 60.93% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q1 | -0.14 SEK | -16.67% |
| 2011 Q4 | -0.14 SEK | -138.91% |
| 2010 Q3 | -0.12 SEK | -9.09% |
| 2010 Q2 | -0.11 SEK | 0.0% |
| 2010 Q4 | -0.12 SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | -3.31 SEK | 92.145% |
| Immunovia AB (publ) | -7.38 SEK | 96.477% |
| Prostatype Genomics AB (publ) | -0.24 SEK | -8.333% |
| SenzaGen AB | -0.91 SEK | 71.429% |
| Spermosens AB | -0.15 SEK | -73.333% |